{"id":23246,"date":"2025-05-13T16:44:21","date_gmt":"2025-05-13T09:44:21","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=23246"},"modified":"2025-05-13T16:44:21","modified_gmt":"2025-05-13T09:44:21","slug":"eligo-bioscience-awarded-5-million-to-advance-breakthrough-genetic-medicine-platform-for-immuno-dermatology","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=23246","title":{"rendered":"Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1533529\/Eligo_Bioscience_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>Funding is part of the call for proposals &#8220;Innovations in\u00a0Biotherapies and Bioproduction,&#8221; coordinated by the Health Innovation Agency under <span class=\"xn-location\">France<\/span> 2030 strategy, operated on behalf of the French government by Bpifrance<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">PARIS<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 13, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, today announced it has secured a <span class=\"xn-money\">$5 million<\/span> grant from the French government to accelerate the advancement and scaling up of Eligo&#8217;s proprietary topical gene delivery platform, designed to enable local production of therapeutic biologics directly by skin-resident bacteria.<\/p>\n<p>\u00a0<\/p>\n<div dir=\"ltr\">   <a href=\"https:\/\/mma.prnasia.com\/media2\/2684935\/Eligo_Bioscience.jpg?p=medium600\" target=\"_blank\"><img decoding=\"async\" title=\"Cross-sectional illustration of human skin treated with a topical Eligobiotics-based gel. The translucent blue gel contains protein-based nanoparticles designed to deliver their DNA payload to bacteria localized within hair follicles, enabling the local expression of therapeutic biologics.\" src=\"https:\/\/mma.prnasia.com\/media2\/2684935\/Eligo_Bioscience.jpg?p=medium600\" alt=\"Cross-sectional illustration of human skin treated with a topical Eligobiotics-based gel. The translucent blue gel contains protein-based nanoparticles designed to deliver their DNA payload to bacteria localized within hair follicles, enabling the local expression of therapeutic biologics.\" align=\"middle\" \/><\/a>   <br \/>   <span>Cross-sectional illustration of human skin treated with a topical Eligobiotics-based gel. The translucent blue gel contains protein-based nanoparticles designed to deliver their DNA payload to bacteria localized within hair follicles, enabling the local expression of therapeutic biologics.<\/span>  <\/div>\n<p>\u00a0<\/p>\n<p>This grant follows recent key milestones for Eligo, including the publication of its microbiome base-editing platform in <i><a href=\"https:\/\/www.nature.com\/articles\/s41586-024-07681-w\" target=\"_blank\" rel=\"nofollow\">Nature<\/a><\/i>, securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to <span class=\"xn-money\">$35 million<\/span>. This latest non-dilutive financial support strengthens Eligo&#8217;s capacity to rapidly advance its clinical pipeline.<\/p>\n<p><b>Scaling up and advancing towards the clinic<\/b><\/p>\n<p>Building on the development of its first-generation CRISPR-based topical therapeutic targeting moderate to severe acne vulgaris, Eligo will now optimize and scale up the bioproduction process of its innovative gene delivery vector ahead of later-stage clinical trials. In this endeavor, Eligo is partnering with Biose Industries, a globally recognized CDMO specializing in microbial fermentation. Biose&#8217;s extensive GMP expertise in scaling complex microbial therapeutics will be instrumental in accelerating Eligo&#8217;s progress toward clinical validation.<\/p>\n<p><i>&#8220;This funding empowers us to establish a robust bioproduction process for our first-in-class topical microbiome-targeting gene-editing therapies, laying the groundwork for expanding into a wide range of immuno-dermatological indications,&#8221; <\/i>said Dr. Xavier Duportet, CEO and Co-Founder of Eligo Bioscience.<i> &#8220;It reinforces our ambition to deliver truly transformative therapeutic solutions, addressing critical medical challenges faced by millions of patients worldwide.&#8221;<\/i><\/p>\n<p><b>Expansion to immuno-dermatology targets<\/b><\/p>\n<p>The skin microbiome plays a pivotal role in cutaneous immune regulation, and commensal bacteria residing within the hair follicle lie in immediate proximity to resident immune cells.<\/p>\n<p>Eligo&#8217;s unique in-situ delivery modality enables to perform in-situ genetic engineering of these commensal bacteria, turning them as localized bioreactors that can express high-potency biologics precisely where immune dysregulation occurs.<\/p>\n<p>The new funding will support the exploration of multiple therapeutic payloads and the build-out of a diversified immuno-dermatology pipeline targeting chronic inflammatory and immune-mediated skin diseases with significant unmet need.<\/p>\n<p><b>For more information about\u00a0Eligo Bioscience, <span class=\"xn-location\">France<\/span> 2030, and Bpifrance:<\/b> <a href=\"http:\/\/eligo.bio\/france2030\" target=\"_blank\" rel=\"nofollow\">eligo.bio\/france2030<\/a>.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><b>Contact :<\/b><br \/><a href=\"mailto:press@eligo-bioscience.com\" target=\"_blank\" rel=\"nofollow\">press@eligo-bioscience.com<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1533529\/Eligo_Bioscience_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>Funding is part of the call for proposals &#8220;Innovations in\u00a0Biotherapies and Bioproduction,&#8221; coordinated by the Health Innovation Agency under <span class=\"xn-location\">France<\/span> 2030 strategy, operated on behalf of the French government by Bpifrance<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">PARIS<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 13, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, today announced it has secured a <span class=\"xn-money\">$5 million<\/span> grant from the French government to accelerate the advancement and scaling up of Eligo&#8217;s proprietary topical gene delivery platform, designed to enable local production of therapeutic biologics directly by skin-resident bacteria.<\/p>\n<p>\u00a0<\/p>\n<div dir=\"ltr\">   <a href=\"https:\/\/mma.prnasia.com\/media2\/2684935\/Eligo_Bioscience.jpg?p=medium600\" target=\"_blank\"><img decoding=\"async\" title=\"Cross-sectional illustration of human skin treated with a topical Eligobiotics-based gel. The translucent blue gel contains protein-based nanoparticles designed to deliver their DNA payload to bacteria localized within hair follicles, enabling the local expression of therapeutic biologics.\" src=\"https:\/\/mma.prnasia.com\/media2\/2684935\/Eligo_Bioscience.jpg?p=medium600\" alt=\"Cross-sectional illustration of human skin treated with a topical Eligobiotics-based gel. The translucent blue gel contains protein-based nanoparticles designed to deliver their DNA payload to bacteria localized within hair follicles, enabling the local expression of therapeutic biologics.\" align=\"middle\" \/><\/a>   <br \/>   <span>Cross-sectional illustration of human skin treated with a topical Eligobiotics-based gel. The translucent blue gel contains protein-based nanoparticles designed to deliver their DNA payload to bacteria localized within hair follicles, enabling the local expression of therapeutic biologics.<\/span>  <\/div>\n<p>\u00a0<\/p>\n<p>This grant follows recent key milestones for Eligo, including the publication of its microbiome base-editing platform in <i><a href=\"https:\/\/www.nature.com\/articles\/s41586-024-07681-w\" target=\"_blank\" rel=\"nofollow\">Nature<\/a><\/i>, securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to <span class=\"xn-money\">$35 million<\/span>. This latest non-dilutive financial support strengthens Eligo&#8217;s capacity to rapidly advance its clinical pipeline.<\/p>\n<p><b>Scaling up and advancing towards the clinic<\/b><\/p>\n<p>Building on the development of its first-generation CRISPR-based topical therapeutic targeting moderate to severe acne vulgaris, Eligo will now optimize and scale up the bioproduction process of its innovative gene delivery vector ahead of later-stage clinical trials. In this endeavor, Eligo is partnering with Biose Industries, a globally recognized CDMO specializing in microbial fermentation. Biose&#8217;s extensive GMP expertise in scaling complex microbial therapeutics will be instrumental in accelerating Eligo&#8217;s progress toward clinical validation.<\/p>\n<p><i>&#8220;This funding empowers us to establish a robust bioproduction process for our first-in-class topical microbiome-targeting gene-editing therapies, laying the groundwork for expanding into a wide range of immuno-dermatological indications,&#8221; <\/i>said Dr. Xavier Duportet, CEO and Co-Founder of Eligo Bioscience.<i> &#8220;It reinforces our ambition to deliver truly transformative therapeutic solutions, addressing critical medical challenges faced by millions of patients worldwide.&#8221;<\/i><\/p>\n<p><b>Expansion to immuno-dermatology targets<\/b><\/p>\n<p>The skin microbiome plays a pivotal role in cutaneous immune regulation, and commensal bacteria residing within the hair follicle lie in immediate proximity to resident immune cells.<\/p>\n<p>Eligo&#8217;s unique in-situ delivery modality enables to perform in-situ genetic engineering of these commensal bacteria, turning them as localized bioreactors that can express high-potency biologics precisely where immune dysregulation occurs.<\/p>\n<p>The new funding will support the exploration of multiple therapeutic payloads and the build-out of a diversified immuno-dermatology pipeline targeting chronic inflammatory and immune-mediated skin diseases with significant unmet need.<\/p>\n<p><b>For more information about\u00a0Eligo Bioscience, <span class=\"xn-location\">France<\/span> 2030, and Bpifrance:<\/b> <a href=\"http:\/\/eligo.bio\/france2030\" target=\"_blank\" rel=\"nofollow\">eligo.bio\/france2030<\/a>.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><b>Contact :<\/b><br \/><a href=\"mailto:press@eligo-bioscience.com\" target=\"_blank\" rel=\"nofollow\">press@eligo-bioscience.com<\/a>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-23246","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23246"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23246\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}